HIST1H2AH | Histone cluster 1, H2ah | | | | | | Tissue enriched |
HIST1H2BI | Histone cluster 1, H2bi | Plasma proteins
| | | | | Tissue enhanced |
HIST1H2BL | Histone cluster 1, H2bl | Plasma proteins
| | | | | Tissue enriched |
HIST1H2BM | Histone cluster 1, H2bm | | | | | | Tissue enhanced |
HIST1H2BO | Histone cluster 1, H2bo | | | | | | Tissue enhanced |
HIST1H3A | Histone cluster 1, H3a | | | | | | Tissue enhanced |
HIST1H3B | Histone cluster 1, H3b | Cancer-related genes
| | | | | Tissue enriched |
HIST1H3F | Histone cluster 1, H3f | | | | | | Tissue enhanced |
HIST1H3H | Histone cluster 1, H3h | | | | | | Tissue enhanced |
HK3 | Hexokinase 3 (white cell) | Enzymes Plasma proteins
| | | | | Tissue enhanced |
HLA-DOB | Major histocompatibility complex, class II, DO beta | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ICOS | Inducible T-cell co-stimulator | CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
IFIT1B | Interferon-induced protein with tetratricopeptide repeats 1B | | | | | | Tissue enriched |
IGSF21 | Immunoglobin superfamily, member 21 | Predicted secreted proteins
| | | | | Tissue enhanced |
IKZF1 | IKAROS family zinc finger 1 (Ikaros) | Cancer-related genes Disease related genes Predicted membrane proteins Transcription factors
| | | | | Tissue enhanced |
IL18RAP | Interleukin 18 receptor accessory protein | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
IL4I1 | Interleukin 4 induced 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
IRF8 | Interferon regulatory factor 8 | Disease related genes Plasma proteins Transcription factors
| | | | | Tissue enhanced |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGAM | Integrin, alpha M (complement component 3 receptor 3 subunit) | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | | | Group enriched |
ITGAX | Integrin, alpha X (complement component 3 receptor 4 subunit) | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KIF21B | Kinesin family member 21B | Plasma proteins
| | | | | Tissue enhanced |
KLHL15 | Kelch-like family member 15 | | | | | | Tissue enhanced |
KLRC3 | Killer cell lectin-like receptor subfamily C, member 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LCK | Lymphocyte-specific protein tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
LCN2 | Lipocalin 2 | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LEF1 | Lymphoid enhancer-binding factor 1 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
LRMP | Lymphoid-restricted membrane protein | Predicted membrane proteins
| | | | | Tissue enhanced |
LTB | Lymphotoxin beta (TNF superfamily, member 3) | Cancer-related genes Plasma proteins
| | | | | Group enriched |
LTF | Lactotransferrin | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LY86 | Lymphocyte antigen 86 | Predicted secreted proteins
| | | | | Tissue enhanced |
MAP4K1 | Mitogen-activated protein kinase kinase kinase kinase 1 | Enzymes
| | | | | Tissue enhanced |
MARCO | Macrophage receptor with collagenous structure | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MFSD2B | Major facilitator superfamily domain containing 2B | Predicted membrane proteins
| | | | | Tissue enriched |
MKI67 | Marker of proliferation Ki-67 | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
MMP8 | Matrix metallopeptidase 8 (neutrophil collagenase) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MPO | Myeloperoxidase | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enriched |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
MYBL2 | V-myb avian myeloblastosis viral oncogene homolog-like 2 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
MYO1G | Myosin IG | | | | | | Tissue enhanced |
NCF1 | Neutrophil cytosolic factor 1 | Disease related genes
| | | | | Tissue enhanced |
NCF4 | Neutrophil cytosolic factor 4, 40kDa | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
NFE2 | Nuclear factor, erythroid 2 | Transcription factors
| | | | | Tissue enriched |